AU2003280867A1 - Specific haplotypes of the mdr1 gene and their use in diagnosis and therapy - Google Patents
Specific haplotypes of the mdr1 gene and their use in diagnosis and therapyInfo
- Publication number
- AU2003280867A1 AU2003280867A1 AU2003280867A AU2003280867A AU2003280867A1 AU 2003280867 A1 AU2003280867 A1 AU 2003280867A1 AU 2003280867 A AU2003280867 A AU 2003280867A AU 2003280867 A AU2003280867 A AU 2003280867A AU 2003280867 A1 AU2003280867 A1 AU 2003280867A1
- Authority
- AU
- Australia
- Prior art keywords
- diagnosis
- therapy
- mdr1 gene
- specific haplotypes
- haplotypes
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 238000003745 diagnosis Methods 0.000 title 1
- 102000054766 genetic haplotypes Human genes 0.000 title 1
- 108090000623 proteins and genes Proteins 0.000 title 1
- 238000002560 therapeutic procedure Methods 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/16—Primer sets for multiplex assays
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/172—Haplotypes
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Hospice & Palliative Care (AREA)
- Biophysics (AREA)
- Oncology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10251236.1 | 2002-11-04 | ||
| DE10251236 | 2002-11-04 | ||
| PCT/EP2003/012294 WO2004042081A1 (en) | 2002-11-04 | 2003-11-04 | Specific haplotypes of the mdr1 gene and their use in diagnosis and therapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2003280867A1 true AU2003280867A1 (en) | 2004-06-07 |
Family
ID=32308471
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2003280867A Abandoned AU2003280867A1 (en) | 2002-11-04 | 2003-11-04 | Specific haplotypes of the mdr1 gene and their use in diagnosis and therapy |
Country Status (2)
| Country | Link |
|---|---|
| AU (1) | AU2003280867A1 (en) |
| WO (1) | WO2004042081A1 (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1669447A4 (en) * | 2003-09-24 | 2007-03-14 | Kyushu Tlo Co Ltd | SNPs IN 5' REGULATORY REGION OF MDR1 GENE |
| US8338648B2 (en) | 2004-06-12 | 2012-12-25 | Signum Biosciences, Inc. | Topical compositions and methods for epithelial-related conditions |
| CN110643699B (en) * | 2019-10-16 | 2020-12-01 | 成都仕康美生物科技有限公司 | Cyclosporin A metabolic gene detection kit and application method thereof |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4147768A (en) * | 1976-09-13 | 1979-04-03 | Interx Research Corporation | Enteric coated digoxin and therapeutic use thereof |
| NZ251211A (en) * | 1992-04-10 | 1997-05-26 | Merrell Dow Pharma | 2'-halomethylidene derivatives, use in treating cancer |
| SK1502002A3 (en) * | 1999-07-30 | 2002-07-02 | Epidauros Biotechnologie Ag | A polynucleotide, a vector, a host cell, method for producing molecular variant mdr-1 protein, mdr-1 protein, an antibody, a nucleic acid molecule and a transgenic animal containing the same and the use thereof |
| US20010038832A1 (en) * | 2000-04-11 | 2001-11-08 | Benjamin Bonavida | Nitric oxide and analogues thereof effectuate sensitization of neoplasm and immunologically undesired tissues to cytotoxicity |
| DE10029404B4 (en) * | 2000-06-15 | 2009-10-29 | Jagotec Ag | Pharmaceutical formulation containing cyclosporin and its use |
| US20040191785A1 (en) * | 2000-11-29 | 2004-09-30 | Ulrich Brinkmann | Methods for diagnosing individuals with an increased risk to develop a deficiency based on mdr1 gene polymorphism |
| US6784156B2 (en) * | 2001-03-05 | 2004-08-31 | Enanta Pharmaceuticals, Inc. | Cyclosporins for the treatment of respiratory diseases |
-
2003
- 2003-11-04 AU AU2003280867A patent/AU2003280867A1/en not_active Abandoned
- 2003-11-04 WO PCT/EP2003/012294 patent/WO2004042081A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| WO2004042081A1 (en) | 2004-05-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2003264282A1 (en) | Phenethanolamine derivatives and their use in the treatment of respiratory diseases | |
| AU2002952993A0 (en) | Therapeutic and diagnostic agents | |
| AU2003298937A1 (en) | Heterocyclic compounds, methods of making them and their use in therapy | |
| AU2002258728A1 (en) | Gene brcc-3 and diagnostic and therapeutic uses thereof | |
| AU2002305151A1 (en) | Gene scc-112 and diagnostic and therapeutic uses thereof | |
| AU2002252976A1 (en) | Hydrazones and their therapeutic use | |
| AU2003286285A1 (en) | Use of fgf-18 in the diagnosis and treatment of memory disorders | |
| AU2003265620A1 (en) | Cardiovascular therapy composition including transfer factor and therapeutic methods including use of the composition | |
| HUP0201997A3 (en) | Polymorphisms in the human mdr-1 gene and their use in diagnostic and therapeutic applications | |
| AU2003209289A1 (en) | Transposable elements in rice and methods of use | |
| AU2003244455A1 (en) | Piperidylcarboxamide derivatives and their use in the treatment of tachykinim-mediated diseases | |
| AU2003280867A1 (en) | Specific haplotypes of the mdr1 gene and their use in diagnosis and therapy | |
| AU2003245858A1 (en) | Uses of ngal-binding substances in the diagnosis and treatment of cancer diseases | |
| AU2003240253A1 (en) | Polymorphisms in the human gene for htr3b and their use in diagnostic and therapeutic applications | |
| AU2002303262A1 (en) | Gene shinc-1 and diagnostic and therapeutic uses thereof | |
| AU2003244498A1 (en) | Polymorphisms in the human gene for tpmt and their use in diagnostic and therapeutic applications | |
| AU2003270097A1 (en) | Immune markers used for diagnosis and therapy in connection with transplant reactions | |
| AU2003264094A1 (en) | Polymorphisms in the human genes for oct1 and their use in diagnostic and therapeutic applications | |
| AU2003244437A1 (en) | Quinoxalinones and their use especially in the treatment of cardiovascular diseases | |
| AU2003240446A1 (en) | Use of mob-5 in pain | |
| AU2003224147A1 (en) | Pax-5-deficient pro-b-cells, methods of producing them and the use of such cells in human therapy | |
| AU2003217432A1 (en) | Angiopoietin-1 in the treatment of disease | |
| AU2002953516A0 (en) | Genetic therapy and genetic modification | |
| AU2003235665A1 (en) | Diagnostic and therapeutic uses of topors | |
| AU2003208289A1 (en) | Deuterated spirocyclopentanimidazolinones and the use thereof in the treatment of cardiovascular diseases |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK6 | Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase |